The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
This inspection is now closed
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
The approval comes after a systematic review of published literature
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
DiaMedica said it plans to launch the trial later in 2026
Subscribe To Our Newsletter & Stay Updated
